加速大分割放疗联合同期全剂量化疗治疗局部晚期非小细胞肺癌的I/II期研究
前瞻性I/II期研究纳入92例III期NSCLC患者,接受加速大分割放疗(58.8 Gy/21次,2.8 Gy/次,4周)联合同期2周期顺铂+长春瑞滨全剂量化疗。中位总生存38个月(95%CI:27-49),中位无进展生存25个月(95%CI:14-36)。≥III级急性食管毒性14%,出现2例毒性死亡及5例可能治疗相关死亡,生存获益但毒性风险需关注。
要点
- III期NSCLC采用AHRT-CHT方案:58.8 Gy/21次联合顺铂+长春瑞滨全剂量化疗,中位OS达38个月。
- ≥III级急性食管毒性发生率14%,3例III级急性肺炎,2例III级晚期肺毒性。
- 治疗3个月内2例毒性死亡,1年内另有5例可能治疗相关死亡,需警惕毒性风险。
核心结论
- 加速大分割放疗联合同期全剂量化疗的生存率令人鼓舞,但毒性和可能毒性死亡的发生率值得关注。
- 研究继续采用该方案,但排除大PTV和主要血管受侵患者以降低毒性死亡风险。
研究设计与样本
- 前瞻性I/II期研究,纳入92例III期NSCLC患者。
- 放疗采用3D-CRT或IMRT计划,58.8 Gy/21次(2.8 Gy/次,4周)。
- 同期化疗2周期:顺铂80 mg/m2 D1和D22;长春瑞滨25 mg/m2 D1、D8、D22和D29,从放疗第1天开始。
- 非血液学毒性采用RTOG-EORTC标准评估,治疗期间每周、治疗后1个月及此后每3个月评估。
主要发现
- 2例未接受处方放疗剂量;22例(24%)仅接受1周期化疗。
- 全组中位随访21.5个月(范围1-65),存活患者中位随访32个月(范围8-65)。
- 13例(14%)发生≥III级急性食管毒性;3例III级急性肺炎;2例III级晚期肺毒性。
- 治疗3个月内2例毒性死亡:致命性咯血1例、食管毒性并发症1例。
- 治疗1年内另有5例可能治疗相关死亡:肺脓肿1例、致命性咯血2例、原因不明死亡2例。
关键数值与推荐
- 放疗剂量58.8 Gy/21次(2.8 Gy/次,4周)。
- 顺铂80 mg/m2 D1和D22;长春瑞滨25 mg/m2 D1、D8、D22和D29。
- ≥III级急性食管毒性13例(14%);III级急性肺炎3例;III级晚期肺毒性2例。
- 中位总生存38个月(95%CI:27-49);中位无进展生存25个月(95%CI:14-36)。
临床怎么用
- III期NSCLC可考虑加速大分割放疗联合同期全剂量化疗,但需密切监测食管和肺毒性。
- 大PTV和主要血管受侵患者应排除,因可能增加毒性死亡风险。
- 治疗期间每周及治疗后定期评估非血液学毒性,关注咯血和食管毒性并发症。
局限性
- I/II期研究,样本量有限(92例),需更大规模研究验证。
- 部分患者未完成处方放疗剂量(2例)或仅接受1周期化疗(22例,24%)。
- 中位随访时间较短(全组21.5个月),晚期毒性评估可能不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We report the results of toxicity and survival in stage III NSCLC patients treated with concurrent accelerated hypofractionated AHRT-CHT within a prospective study. METHODS: 92 patients received 3D-CRT or IMRT-planned RT: 58.8 Gy /21 fractions (2.8 Gy/fraction, 4 weeks) with 2 cycles of CHT (Cisplatin 80 mg/m2 D1 and D22; and Vinorelbine 25 mg/m2, D1, D8, D22, and D29) started with D1 of RT. Non-hematological toxicity was evaluated using RTOG-EORTC criteria, every week during treatment, one month after treatment completion, and every three months thereafter. RESULTS: Two patients did not receive the prescribed RT dose; 22 (24%) received only one CHT cycle. Median follow-up was 21.5 months (range: 1-65) for all patients and 32 months (range: 8-65) for living patients. There were: 13 (14%) cases of grade ≥III acute esophageal toxicity; 3 grade III acute pneumonitis, and 2 grade III late pulmonary toxicities. Two toxic deaths occurred within 3 months after treatment: fatal hemoptysis (1) and complications of esophageal toxicity (1). Five other deaths that occurred within one year after treatment were probably treatment-related: lung abscess (1), fatal hemoptysis (2), death from undetermined cause (2). Median overall survival was 38 months (95%CI:27-49), median progression free survival was 25 months (95%CI:14-36). CONCLUSIONS: Survival rates are encouraging, but the observed rate of toxic and probably toxic deaths is of potential concern. We proceed with the use of AHRT with concomitant full dose CHT, but patients with large PTV and major vascular abutment are excluded due to potentially increased risk of toxic death.
引用
- Glinski K, Socha J, Wasilewska-Tesluk E, et al. Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: A phase I/II study. Radiother Oncol. 2020. PMID: 32388152. doi:10.1016/j.radonc.2020.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。